Company news
Sanofi Sa (EURONEXT:SAN) news
Sanofi Sa news releases on 6ix. Latest, Oct 6, 2026: Press Release : Availability of the aide-mémoire for Q3 2026 results
Press releases & updates
Press Release : Availability of the aide-mémoire for Q3 2026 results
October 6, 2026
Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
October 2, 2026
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
September 30, 2026
Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
September 30, 2026
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
October 1, 2026
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
October 1, 2026
Sanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment
September 16, 2026
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
September 14, 2026
Communiqué de presse : Sanofi et Cheplapharm créent un nouveau partenariat stratégique autour des médicaments matures
September 13, 2026
Sanofi: Information concerning the total number of voting rights and shares - August 2026
September 11, 2026
Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID™
September 10, 2026
Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
September 8, 2026
Sanofi: Information concerning the total number of voting rights and shares - July 2026
August 13, 2026
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2026
August 12, 2026
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
August 4, 2026
Communiqué de presse : MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques
August 3, 2026
Press Release: Sanofi’s half-year financial report for 2026
July 30, 2026
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
July 21, 2026
Aqemia and Sanofi Expand Their Research Collaboration
July 17, 2026
Sanofi: Information concerning the total number of voting rights and shares - June 2026
July 10, 2026
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
July 10, 2026
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
July 10, 2026
Press Release: Availability of the aide-mémoire for Q2 2026 results
July 1, 2026
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
June 30, 2026
DoH and Sanofi Partner to Advance Vaccine Innovation
June 22, 2026
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
June 23, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
June 23, 2026
Sanofi appoints Paulo Fontoura as Global Head of R&D
June 22, 2026
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
June 19, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
June 19, 2026
Sanofi: Information concerning the total number of voting rights and shares – May 2026
June 15, 2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
June 12, 2026
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
June 12, 2026
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
June 10, 2026
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
June 8, 2026
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
June 8, 2026
Sanofi launches 2026 global employee stock purchase plan
June 4, 2026
Sanofi Chooses Snowflake to Accelerate its AI-Powered Drug Development
June 2, 2026
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
May 28, 2026
Sanofi: Information concerning the total number of voting rights and shares - April 2026
May 19, 2026
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
May 6, 2026
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
May 5, 2026
Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients
May 4, 2026
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
April 29, 2026
Press Release: Sanofi successfully prices 2.3 billion of bond issue
April 24, 2026
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
April 24, 2026
Press Release: Q1 2026: double-digit sales and business EPS growth
April 23, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
April 22, 2026
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
April 22, 2026
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
April 22, 2026